Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
Summary of findings table ‐ Off‐midline closure (Karydakis flap) showed no clear difference in proportion of wounds healed compared with off‐midline closure (Limberg flap) (low certainty).
Summary of findings table ‐ Off‐midline closure (Karydakis flap) showed no clear difference in recurrence rate compared with off‐midline closure (Limberg flap) (low certainty).
Summary of findings table ‐ Off‐midline closure (Karydakis flap) showed no clear difference in wound infection compared with off‐midline closure (Limberg flap) (low certainty).
Summary of findings table ‐ Off‐midline closure (Karydakis flap) showed no clear difference in wound dehiscence compared with off‐midline closure (Limberg flap) (low certainty).
It is very uncertain whether summary of findings table ‐ Off‐midline closure changes proportion of wounds healed compared with conventional midline closure (very low certainty).
The review found no eligible studies for this question.
Summary of findings table ‐ Off‐midline closure probably leads to lower recurrence rate compared with conventional midline closure (moderate certainty).
Summary of findings table ‐ Off‐midline closure probably leads to lower wound infection compared with conventional midline closure (moderate certainty).
Summary of findings table ‐ Off‐midline closure may leads to lower wound dehiscence compared with conventional midline closure (low certainty).
The review found no eligible studies for this question.
Summary of findings table ‐ Off‐midline closure may leads to higher proportion of wounds healed compared with tension‐free midline closure (low certainty).
Balloon (Foley or ATAD) showed no clear difference in vaginal delivery not achieved in 24 hours compared with vaginal prostaglandin E2 (low certainty).
Balloon (Foley or ATAD) may leads to higher caesarean section compared with low‐dose vaginal misoprostol (low certainty).
It is very uncertain whether balloon (Foley or ATAD) changes serious neonatal morbidity or perinatal death compared with low‐dose vaginal misoprostol (very low certainty).